Yangbo Feng

3.3k total citations · 1 hit paper
65 papers, 2.6k citations indexed

About

Yangbo Feng is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Yangbo Feng has authored 65 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Molecular Biology, 17 papers in Organic Chemistry and 11 papers in Oncology. Recurrent topics in Yangbo Feng's work include Melanoma and MAPK Pathways (20 papers), Protein Kinase Regulation and GTPase Signaling (19 papers) and Chemical Synthesis and Analysis (13 papers). Yangbo Feng is often cited by papers focused on Melanoma and MAPK Pathways (20 papers), Protein Kinase Regulation and GTPase Signaling (19 papers) and Chemical Synthesis and Analysis (13 papers). Yangbo Feng collaborates with scholars based in United States, China and Germany. Yangbo Feng's co-authors include Philip V. LoGrasso, Yanlu Xiong, Tianyun Qiao, Yong Han, Lintao Jia, Xiaofei Li, Giuseppe Melacini, Rongshi Li, Olivier Defert and Kevin Burgess and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Neuroscience and Blood.

In The Last Decade

Yangbo Feng

63 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy

2018 480 citations Yangbo Feng, Yanlu Xiong et al. profile →

Peers

Countries citing papers authored by Yangbo Feng

Since Specialization

Citations

This map shows the geographic impact of Yangbo Feng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yangbo Feng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yangbo Feng more than expected).

Fields of papers citing papers by Yangbo Feng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yangbo Feng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yangbo Feng. The network helps show where Yangbo Feng may publish in the future.

Co-authorship network of co-authors of Yangbo Feng

This figure shows the co-authorship network connecting the top 25 collaborators of Yangbo Feng. A scholar is included among the top collaborators of Yangbo Feng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yangbo Feng. Yangbo Feng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structural study of selectivity mechanisms for JNK3 and p38α with indazole scaffold probing compounds 2025 ·Journal of Molecular Structure ·HaJeung Park, Yangbo Feng	1
2	The Cyclin-G Associated Kinase (GAK) Is a Critical Targetable Dependency for Successful Mitosis By Diffuse Large B-Cell Lymphomas Linked to Retinoblastoma Loss of Function 2024 ·Blood ·(unknown), (unknown), (unknown), Lingxiao Li, Pamela Younes, (unknown), (unknown), (unknown), (unknown), Daniel Bilbao, Stephan C. Schürer, Vance Lemmon, Francesco Maura, Yangbo Feng, (unknown), Jonathan H. Schatz	0
3	Targeted Therapy Development in Acute Myeloid Leukemia 2023 ·Biomedicines ·Tulasigeri M. Totiger, (unknown), (unknown), (unknown), (unknown), (unknown), Yangbo Feng, Justin Taylor	30
4	Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model 2022 ·Cancer Immunology Immunotherapy ·Tianyun Qiao, Jinbo Zhao, (unknown), Yanlu Xiong, Wenwen Guo, Fancheng Meng, Hui Li, Yangbo Feng, Hui Xu, Changhong Shi, (unknown)	12
5	The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion 2021 ·Scientific Reports ·(unknown), (unknown), (unknown), Jann N. Sarkaria, Zane Zeier, Yangbo Feng, Nagi G. Ayad	18
6	A New Quantitative Cell-Based Assay Reveals Unexpected Microtubule Stabilizing Activity of Certain Kinase Inhibitors, Clinically Approved or in the Process of Approval 2020 ·Frontiers in Pharmacology ·Sacnicte Ramírez‐Ríos, (unknown), Leticia Peris, Caroline Barette, (unknown), Yangbo Feng, Marie‐Odile Fauvarque, Annie Andrieux, Karin Sadoul, Laurence Lafanéchère	7
7	Discovery of (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide as potent and isoform selective ROCK2 inhibitors 2019 ·Bioorganic & Medicinal Chemistry ·(unknown), Yan Yin, Lianhua Zhao, Yangbo Feng	9
8	Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration 2016 ·Journal of Neuroscience ·Erik G. Gentry, Benjamin W. Henderson, Andrew E. Arrant, Marla Gearing, Yangbo Feng, Nicole C. Riddle, Jeremy H. Herskowitz	73
9	Discovery of bis-aryl urea derivatives as potent and selective Limk inhibitors: Exploring Limk1 activity and Limk1/ROCK2 selectivity through a combined computational study 2015 ·Bioorganic & Medicinal Chemistry ·(unknown), (unknown), Wei Deng, Yan Yin, (unknown), (unknown), (unknown), Yu Lin Jiang, Yangbo Feng	14
10	Development of highly selective casein kinase 1δ/1ε (CK1δ/ε) inhibitors with potent antiproliferative properties 2013 ·Bioorganic & Medicinal Chemistry Letters ·Mathieu Bibian, Ronald J. Rahaim, Jun Yong Choi, Yoshihiko Noguchi, Stephan C. Schürer, Wei‐Min Chen, Shima Nakanishi, Konstantin Licht, Laura H. Rosenberg, Lin Li, Yangbo Feng, Michael D. Cameron, Derek R. Duckett, John L. Cleveland, William Roush	63
11	Pharmacologic Inhibition of ROCK2 Suppresses Amyloid-β Production in an Alzheimer's Disease Mouse Model 2013 ·Journal of Neuroscience ·Jeremy H. Herskowitz, Yangbo Feng, Alexa L. Mattheyses, Chadwick M. Hales, Lenora A. Higginbotham, Duc M. Duong, Thomas J. Montine, Juan C. Troncoso, Madhav Thambisetty, Nicholas T. Seyfried, Allan I. Levey, James J. Lah	130
12	Rho kinase inhibitors: a patent review (2012 – 2013) 2013 ·Expert Opinion on Therapeutic Patents ·Yangbo Feng, Philip V. LoGrasso	42
13	Imidazopyridines as selective CYP3A4 inhibitors 2012 ·Bioorganic & Medicinal Chemistry Letters ·Xinyi Song, Xiaohai Li, Claudia Ruiz, Yan Yin, Yangbo Feng, Theodore M. Kamenecka, Michael D. Cameron	5
14	Rho Kinase (ROCK) Inhibitors and Their Application to Inflammatory Disorders 2009 ·Current Topics in Medicinal Chemistry ·Philip V. LoGrasso, Yangbo Feng	59
15	Benzimidazole- and benzoxazole-based inhibitors of Rho kinase 2008 ·Bioorganic & Medicinal Chemistry Letters ·E. Hampton Sessions, Yan Yin, Thomas D. Bannister, Amiee Weiser, (unknown), Jennifer Pocas, Michael D. Cameron, Claudia Ruiz, Lin Li, Stephan C. Schürer, Thomas Schröter, Philip V. LoGrasso, Yangbo Feng	82
16	Chroman-3-amides as potent Rho kinase inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·Yen‐Ting Chen, Thomas D. Bannister, Amiee Weiser, (unknown), Lin Li, Claudia Ruiz, Michael D. Cameron, Stephan C. Schürer, Derek R. Duckett, Thomas Schröter, Philip V. LoGrasso, Yangbo Feng	45
17	Structure–activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II 2006 ·Bioorganic & Medicinal Chemistry Letters ·Yangbo Feng, Michael D. Cameron, (unknown), (unknown), Lin Li, Claudia Ruiz, Thomas Schröter, Philip V. LoGrasso	39
18	Resin effects in solid phase SnAr and Sn2 macrocyclizations 2000 ·Biotechnology and Bioengineering ·Yangbo Feng, Kevin Burgess	12
19	Cold denaturation of a synthetic collagen mimetic 1998 ·Biopolymers ·Yangbo Feng, Elizabeth A. Jefferson, (unknown)	4
20	A labeled guanidine ligand for studying sweet taste 1998 ·Bioorganic & Medicinal Chemistry Letters ·Yangbo Feng, Kevin Burgess, (unknown), (unknown), D. Scott Linthicum	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact